Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 153Carcinoma, Non-Small-Cell Lung 94Neoplasms 57Breast Neoplasms 50Urinary Bladder Neoplasms 47Neoplasm Metastasis 43Lung Neoplasms 41Ovarian Neoplasms 36Cholangiocarcinoma 31Lymphoma 20Sarcoma 19Gallbladder Neoplasms 19Fallopian Tube Neoplasms 19Lymphoma, Large B-Cell, Diffuse 18Biliary Tract Neoplasms 18Recurrence 15Lymphoma, Non-Hodgkin 15Adenocarcinoma 14Hodgkin Disease 13Carcinoma, Transitional Cell 13Bile Duct Neoplasms 13Carcinoma 12Colorectal Neoplasms 10Head and Neck Neoplasms 8Carcinoma, Renal Cell 8Urethral Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7Carcinoma, Ovarian Epithelial 7Adenocarcinoma of Lung 7Uterine Cervical Neoplasms 6

Interventions

Gemcitabine 4pembrolizumab 2Leucovorin 2Irinotecan 2Fluorouracil 2Albumin-Bound Paclitaxel 24-fluorobenzoyl-TN-14003 2regorafenib 1olaparib 1irinotecan sucrosofate 1ibrutinib 1adavosertib 1Paclitaxel 1PEGPH20 1Oxaliplatin 1Drug Therapy 1Docetaxel 1Cisplatin 1Capecitabine 1BKT140 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Metastatic Pancreatic Adenocarcinoma × Gemcitabine × Clear all
NCT02383433 2023-10-23

Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer

Case Comprehensive Cancer Center

Phase 2 Terminated
2 enrolled 8 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT02324543 2023-07-21

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
47 enrolled 22 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT02194829 2023-04-25

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Completed
8 enrolled 9 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT02562898 2021-05-06

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

University of California, San Francisco

Phase 1/2 Completed
18 enrolled 15 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡